Caliway Receives FDA Clearance for Phase 2 Trial of CBL-514 Combination Therapy
Caliway has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for a Phase 2 trial evaluating CBL-514 in combination with tirzepatide.
Caliway has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for a Phase 2 trial evaluating CBL-514 in combination with tirzepatide. Additionally, the company has initiated patient enrollment for the pivotal Phase 3 trial, SUPREME-01.
The company announced today that the Phase 2 trial, designated CBL-0201WR, will proceed. This study will assess the efficacy and safety of CBL-514 when administered in combination with tirzepatide, a medication already approved for type 2 diabetes and chronic weight management.
The SUPREME-01 trial, identified by protocol CBL-0301, represents Caliway's key pivotal Phase 3 study. Its objective is to gather the data necessary for potential final approval of the CBL-514 therapy. Patient enrollment for this significant trial is now underway, and it is expected to yield critical information regarding the treatment's clinical benefits.
These advancements mark substantial progress in Caliway's drug development pipeline. The FDA's clearance for the Phase 2 trial and the commencement of the Phase 3 trial indicate the company is moving toward broader clinical validation for the CBL-514 combination therapy. The outcomes of these studies will be crucial for the therapy's future market presence.